NCT06314737Completed
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Assessment of Efficacy of New Adjuvant Therapy in Locally Advanced Rectal Cancer
Source: ClinicalTrials.gov · Last updated 18 Mar 2024
Brief summary (registry, in English)
This study analyzed the efficacy differences between neoadjuvant therapy and direct surgical treatment in patients with locally advanced rectal cancer in the real world. The aim was to evaluate the impact of neoadjuvant therapy on overall survival, disease-free survival, and local recurrence-free survival in patients with locally advanced rectal cancer, explore the population benefiting most from neoadjuvant therapy, and provide evidence-based medicine for the benefits of neoadjuvant therapy in patients with colorectal cancer in the real world.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3515 (actual)
- First submitted
- 9 Mar 2024
- Start date
- 2 Oct 2010
- Primary completion date
- 6 Dec 2018
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Diseases
- Childhood cancers
- NCT number
- NCT06314737
What you commit to
- Study type: Observational
- Participants enrolled: 3515
- From 2 Oct 2010 to the primary completion date, 6 Dec 2018
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrently diagnosed with multiple colorectal cancers or concomitant other malignant tumors;
- Did not undergo surgical treatment;
Other illness
- Locally recurrent rectal cancer;
- Upper rectal cancer or cancer at the rectosigmoid junction.
Other
- Initial diagnosis suggests suspicious distant metastasis;
- Histological diagnosis of rectal squamous cell carcinoma, adenocarcinoma, or neuroendocrine carcinoma;
- MRI information lost;
Who the study is looking for
- Pathological examination confirmed primary rectal adenocarcinoma;
- Pelvic MRI or abdominal-pelvic CT at initial diagnosis diagnosed as T3-4 or N+;
- Thoracoabdominal CT indicated no evidence of distant metastasis;
- Distance from the tumor lower margin to the anal verge ≤12cm;
- Underwent surgical treatment.
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.